Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

ABSTRACT:

Background

We compare the effect of 4 different antiretroviral regimens on limb and visceral fat.

Methods

A5224s was a substudy of A5202, a trial of human immunodeficiency virus type 1 (HIV-1)-infected, treatment-naive subjects randomized to blinded abacavir-lamivudine (ABC-3TC) or tenofovir DF-emtricitabine (TDF-FTC) with open-label efavirenz (EFV) or atazanavir-ritonavir (ATV-r). The primary endpoint was the presence of lipoatrophy (≥ 10% loss of limb fat) at week 96 by intent-to-treat (ITT) analysis. Secondary endpoints included changes in limb and visceral fat. Statistical tests included linear regression, binomial, two-sample t test, and Fisher's exact test.

Results

A5224s enrolled 269 subjects; 85% were male, and 47% were white non-Hispanic. The subjects had a m

SUBMITTER: McComsey GA 

PROVIDER: S-EPMC3165963 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature